Abdelghani Jebahi

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.

S. Lheureux, L. Poulain, M. Guercio, 2014, Cancer letters.

18 F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/ mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer 1,2

S. Lheureux, L. Poulain, N. Aide, 2013 .

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737

L. Poulain, P. Gauduchon, E. Abeilard, 2016, Molecular Cancer Therapeutics.

18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer

S. Lheureux, L. Poulain, N. Aide, 2013 .

(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.

S. Lheureux, L. Poulain, N. Aide, 2013, Translational Oncology.